Loading...
Loading...
BBIO| Name | Value |
|---|---|
| Revenues | 1.6M |
| Cost of Revenue | 0.6M |
| Gross Profit | 1.0M |
| Operating Expense | 144.2M |
| Operating I/L | -146.1M |
| Other Income/Expense | -14.6M |
| Interest Income | 4.5M |
| Pretax | -160.7M |
| Income Tax Expense | 19.3M |
| Net Income/Loss | -157.9M |
BridgeBio Pharma, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of medicines for genetic diseases. With a robust pipeline of 30 development programs, the company focuses on product candidates at various stages of development, including small molecule stabilizers, gene transfer products, and antagonists for conditions such as TTR amyloidosis-cardiomyopathy, achondroplasia, congenital adrenal hyperplasia, Autosomal Dominant Hypocalcemia Type 1, and hyperoxaluria. BridgeBio Pharma, Inc. generates revenue through the licensing and collaboration agreements with research institutions and the development of treatments for genetic, oncology, and gene therapy diseases.
